Updates: Company News - Page 2
Covid-19 action plan – A message to our customers, collaboration partners & colleagues
As we all come to terms with the extraordinary and rapidly changing global situation caused by Covid-19, I would like to update you on the plans we have in…
Read update
NB win Phase II of CRACK IT Challenge 29: ImmuLiver
Newcells Biotech are excited to announce that they are Phase II contract winners of the NC3Rs-funded CRACK IT Challenge (named ImmuLiver). They have been awarded a further funding to…
Read update
Newcells Biotech acquires IP for retinal organoids
Newcells Biotech is pleased to announce the acquisition of intellectual property pertaining to the methodology for the differentiation of three-dimensional retinal organoids from…
Read updateNB win Phase I of CRACK IT Challenge 29: ImmuLiver – securing £99,711 funding
Newcells Biotech are one…
Read update
Looking forward: A year in review
2018 has been a significant year for Newcells Biotech. We have secured substantial investment, launched new, ground-breaking products, attended global events and expanded our every growing team. Here are some of…
Read update
ESTIV 2018 International Congress
Congress Round-Up The International Congress on In Vitro Toxicology (ESTIV2018) organised by the European Society of Toxicology was held in Berlin this October 2018. This year marks its 20th meeting, with the general theme of new…
Read update
Leading drug transport & drug toxicity expert, Dr Colin Brown joins NB
Newcells Biotech has announced that Dr Colin Brown, one of the world’s leading experts on drug transport and drug toxicity in kidney will join the company as Director of ADMET Technology….
Read update
22nd North American ISSX Meeting – Montréal, Canada (15th-19th July)
The meeting brings together individuals who are working on drug/xenobiotic research across a diverse range of fields such as clinical pharmacology and therapeutics, toxicology, oncology, endocrinology, physiology, biochemistry, medicinal…
Read update
NB secures £2M investment from NVM Private Equity & Northstar Ventures to accelerate hiPSC growth
Founded on the technology of Prof Lyle Armstrong and Prof Majlinda Lako from Newcastle University, the company is at the forefront of the production and differentiation of human induced…
Read update
17th Annual World Preclinical Congress – Boston, MA (18th-21st June)
Dr Brown is the developer of the aProximateTM assay for measuring kidney transporter and nephrotoxicity licensed exclusively to Newcells Biotech. The World Preclinical Congress is a key networking event focusing on…
Read update
FMS Post-Doc Symposium 2018 – Newcastle University (15th June 2018)
Dr Chichagova will be talking about Retinitis Pigmentosa, one of the most common forms of inherited blindness affecting over 1 million people worldwide.With no effective treatment available for Retinitis…
Read update
Dr Chichagova awarded best In Vitro Toxicology Society poster
Using statistical modelling, Dr Chichagova was able to improve the differentiation outcome of human induced pluripotent stem cells to retinal organoids, which were subsequently successfully tested with a toxicologically relevant test compound.
Read update
